The global healthcare cybersecurity market size is estimated to reach $12.6 billion by 2030, growing at CAGR of 14% during the forecast period. Digitally stored information is prone to hacking and manipulation by cyber criminals. The concern is validated by the fact that more than 5.1 million records are compromised due to data breaches every day. In 2016, close to 1,800 incidents of data breaches were reported across all the industries; in total, almost 1.4 billion data records were lost or sto...

TThe global Back of The Eye Disorders Drugs and Technologies Market is expected to be worth $22.9 billion by 2030. According to the World Health Organization, close to 250 million individuals, including 36 million blind people, presently suffer from some form of vision impairment. Current projections also indicate that, in the US alone, the total economic burden related to vision loss is expected to reach approximately USD 715 billion by 2050. In fact, chronic eye diseases are considered to be o...

The cancer stem cell therapies market, valued at USD 2.8 billion in 2024, is projected to grow to USD 3.1 billion in 2025 and USD 8.0 billion by 2035, representing a CAGR of 10.0% during the forecast period. Over time, the development of CSCs has been shown to be associated with several signaling pathways, which regulate the survival and proliferation of these cells. Presently, a number of initiatives are underway to explore specific targets that can be used to selectively eliminate cancer stem...

The global non-antibody protein scaffolds drugs / diagnostics market is expected to be worth $6.2 billion by 2030, representing a CAGR of of 42% during the forecast period. Although the concept of non-antibody protein scaffolds was conceived more than a decade ago, this field has gained popularity in recent years. The first product candidate was launched in 1986; since then, they have been used for the treatment of a myriad of diseases, including cancer, inflammatory diseases and infectious dise...

The global antibody humanization market, valued at USD 5.7 billion in 2024, is projected to reach USD 6.2 billion in 2025 and USD 14.9 billion by 2035, representing a CAGR of 9.1% during the forecast period. The growing industry has faced / continues to face several challenges. One of the biggest hurdles to the growth of antibody-based products has been the lack of technical know-how across different stages of drug discovery. This situation is particularly true for the more traditional pharmaceu...

Amongst the available energy sources, non-renewables (including fossil fuels and nuclear energy) have a share of about 76.3% and renewables have a share of about 23.7%, in global electricity production. The Paris Agreement at the 21st Conference of Parties (COP), the first ever legally binding global climate deal, was signed by 195 countries in 2015, where it was decided to limit the global average temperature rise to 1.5C till the year 2100, by reducing carbon emissions. As a result of the afor...

The global oncology drug discovery services market to grow at an annualized growth rate of 6.2% during the forecast period. The process of drug discovery is extremely demanding, both in terms of capital expenses and time. Specifically, the oncology market, with an estimated global prevalence of 32 million, imposes a heavy burden on the healthcare system. Over the years, outsourcing has emerged as a popular trend in the pharmaceutical and biotechnology industry, and has demonstrated the potential...

The global non-invasive prenatal testing and newborn screening market is likely be worth $8.2 billion by 2027, representing a CAGR of 15%. It has been estimated that close to 131 million babies are born each year across the globe. Of these, approximately 7.9 million are born with birth defects. In fact, more than 7,000 genetic disorders have been identified so far and the number is rising. Consequently, prenatal testing (primarily Non-invasive prenatal testing (NIPT)) and newborn screening have...

It is predicted that the global economy will increase by three-folds between now and 2050. This, in turn, is likely to result in increased energy demands.According to Enerdata Energy Statistical Yearbook 2016, electricity demand has more than doubled between 1990 and 2015 to reach 20,568 TWh. This demand is projected to grow even further; in fact, by 2035, the growth is expected to be in the range of 69% to 81%. As the global economy aims for energy security, renewable energy sources such as sol...

The global cancer metabolism therapeutics market, valued at USD 5.5 billion in 2024, is projected to reach USD 7.0 billion in 2025 and USD 53.6 billion by 2035, representing a CAGR of 22.5% during the forecast period. Cancer metabolism is based on the principle that cancer cells, as compared to normal cells, have different metabolic activities in order to support their enhanced energy and anabolic requirements. The pioneering discovery by Otto Warburg in the middle of the 20th century led to the...

The global BCMA targeted therapies market, valued at USD 9.2 billion in 2024, is projected to reach USD 11.8 billion in 2025 and USD 85.9 billion by 2035, representing a CAGR of 21.9% during the forecast period. B-cell maturation antigen (BCMA), an important biomarker of the B-cells, has emerged as a promising therapeutic target for the treatment of multiple myeloma and other hematological malignancies. The antigen is universally expressed on the surface of multiple myeloma cells. The research f...

Lupus is a serious, potentially fatal, autoimmune disease that attacks healthy tissue. It is worth metioning that Benlysta

The rheumatoid arthritis market, valued at USD 27.8 billion in 2024, is projected to reach USD 28.8 billion in 2025 and USD 40.1 billion by 2035, representing a CAGR of 3.4% during the forecast period. Several biopharmaceutical companies have been active in this area since last few years while others have recently stepped in. Apart from focusing on already established mechanisms of action, these companies are trying to offer novel and innovative treatment options. A number of collaborations and...

The global antibacterial drug resistance market, valued at USD 9.1 billion in 2024, is projected to reach USD 9.8 billion in 2025 and USD 18.8 billion by 2035, representing a CAGR of 6.7% during the forecast period. Several companies have made an attempt to develop new generation antibiotics that can combat widespread antibiotic drug resistance. These antibiotics are either the improved derivatives of existing antibiotics or combination products of antibiotics and β-lactamase inhibitors. In add...

The global ubiquitin enzymes market, valued at USD 3.0 billion in 2024, is projected to reach USD 3.3 billion in 2025 and USD 8.5 billion by 2035, representing a CAGR of 9.8% during the forecast period. The ubiquitin proteasome system (UPS) is one of the key protein degradation pathway involved in the control of protein homeostasis and turnover that mediates the regulation of several cellular processes. The UPS consists of two separate consecutive steps, ubiquitination and proteasomal degradatio...

The PDE inhibitors market, valued at USD 6.3 billion in 2024, is projected to reach USD 6.7 billion in 2025 and USD 12.7 billion by 2035, representing a CAGR of 6.6% during the forecast period. The success of the marketed PDE drugs has prompted several industry players to undertake initiatives in this area. The fragmented nature of the market is expected to increase the pace of innovation; as more molecules advance to late stage development and eventually get commercialized, we expect the new en...

The global dendritic cell cancer vaccines market is expected to reach $3.2 billion by 2030, growing at an annualized rate of over 20.7%. It is worth noting that in 2016, an estimated 1.7 million new cancer cases were reported in the US alone. Furthermore, as projected by the WHO, the annual incidence of cancer worldwide is expected to rise to 24 million by 2035. As a result, many pharmaceutical companies are working on identifying ways to improve treatment methods, as well as develop new cancer...

The smart wearables market, valued at USD 92.12 billion in 2024, is projected to grow to USD 113.7 billion in 2025 and USD 647.1 billion by 2035, representing a CAGR of 19.0% during the forecast period. Several start-ups, with innovative wearables, have surfaced in the past 6-7 years and have continuously encouraged the use of novel technologies. A sizeable proportion of these companies are focused on gaining foothold in the field of monitoring & diagnosis and wearables offering therapeutic bene...

The global intraocular pressure devices market is expected to reach USD 2.8 billion by 2026, growing at a CAGR of 83.9%. An imbalance in the production and / or drainage of aqueous humor within the eye is known to lead to an increase in intraocular pressure (IOP). Notably, it has been observed that this disease is controlled only in around 50% of patients who have been treated with some form of laser therapy; the effect usually wears off after a period of 5 years. Therefore, in the current scen...

The global HDAC inhibitors market is estimated to grow from USD 1.2 billion in 2024 to reach USD 1.3 billion in 2025 and USD 2.8 billion by 2035, representing a higher CAGR of 7.8% during the forecast period. Currently, HDACs are widely being studied as a promising therapeutic target. HDAC inhibitors can be classified into four main categories based on the structural characteristics of the Zn2+ binding domain. These include hydroxamic acids, cyclic peptides, short-chain fatty acids and benzamide...